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Abstract
Background: Octreotide is generally administered based on the surgeon's interpretation of perceived
risk for pancreatic fistula at the time of pancreaticoduodenectomy (PD).
Methods: A single-institution, prospective randomized trial was conducted between April 2009 and
December 2011 involving 62 PD patients who were randomized to receive octreotide (100 mg subcuta-
neously every 8 h; n = 32) or placebo (n = 30). Pancreatic juice output was measured after the operation
using a catheter inserted into the pancreatic duct. Postoperative complications were recorded.
Results: No significant differences in median output were found between the octreotide (82.5 ml)
and placebo (77.5 ml) groups (P = 0.538). Median total output was significantly lower in patients with
adenocarcinoma compared with those with periampullary tumours (P = 0.004) and in patients with a duct
diameter of >5 mm compared with those with a duct diameter of <5 mm (P = 0.001). There were no
significant differences in overall morbidity between the octreotide and placebo groups (P = 0.819). Grade
B pancreatic fistula (International Study Group for Pancreatic Fistula) was observed in two and three
patients in the octreotide and placebo groups, respectively.
Conclusions: Morbidity did not differ significantly between the groups. This study did not demonstrate
an inhibitory effect of octreotide on exocrine pancreatic secretion. Based on these results, the routine use
of octreotide after PD cannot be recommended.
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Introduction
Although mortality rates after pancreaticoduodenectomy (PD)
have fallen, morbidity remains as high as 28–58%.1,2 Incidences of
postoperative pancreatic fistula (POPF) in patients undergoing
PD lie in the range of 5–35%.3 Clinically relevant POPF is
the major contributor to postoperative morbidity and is usually
caused by leakage from the pancreatoenteric anastomosis.4,5 If it is
not controlled, POPF may lead to secondary septic and haemor-
rhagic complications, organ failure and death. Although attempts
have been made to decrease the incidence of POPF by improving
techniques for reconstructing the pancreatoenteric anastomosis
or optimizing its placement, no effective strategy for the preven-
tion of POPF has yet been found.6–8
Somatostatin and its analogues are known to have an inhibitory
effect on the exocrine secretion of the pancreas.9 These drugs
had been presumed to reduce the rate of pancreatic fistula. The
concept originated in 1979, when Klempa et al.10 first reported
that somatostatin reduced the incidence of complications after
PD. Somatostatin has a short half-life of 1–2 min and must be
administered by continuous i.v. infusion. This can decrease the
patient’s mobility. By contrast, octreotide has a half-life of
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120 min, which allows intermittent subcutaneous dosing sched-
ules. Several double-blinded multicentre randomized controlled
trials (RCTs) have suggested a statistically significant decrease in
overall postoperative complications after pancreatectomy with the
use of perioperative octreotide.11–13 The majority of these studies
included patients with chronic pancreatitis who would be
expected to show a lower incidence of pancreatic fistula.14 Other
studies reported no statistically significant benefit of the periop-
erative use of octreotide.15–20 A study by a pancreatic surgery group
failed to show a decrease in postoperative complications after
major pancreatectomy with the use of vapreotide.21 The results of
meta-analyses are also conflicting.22–26 A recent meta-analysis
concluded that the use of somatostatin and its analogues does
not significantly reduce postoperative complications after PD.27
Therefore, despite 20 years of the clinical use of somatostatin and
its analogues to prevent pancreatic fistula, evidence of the benefit
of its use is still lacking and is required to establish clear recom-
mendations or guidelines.
Other studies have attempted to clarify the effect of somatosta-
tin on remnant exocrine secretion and related morbidity in
patients undergoing PD for malignancy.28,29 In both studies, soma-
tostatin administered i.v. reduced the incidence and severity of
pancreas-related complications, but its effect on the amount of
pancreatic secretion was difficult to demonstrate.
Despite the contradictory results, octreotide is generally admin-
istered according to the surgeon’s interpretation of perceived risk
for fistula development at the time of operation.
The aim of this study was to evaluate the effect of octreotide
on exocrine secretion of the pancreatic remnant after PD and to
assess the efficacy of this drug in the prevention of pancreas-
specific complications in patients undergoing PD for pancreatic
and periampullary lesions, excluding chronic pancreatitis.
Materials and methods
Patients undergoing elective PD between April 2009 and Decem-
ber 2011 in the Biliopancreatic Unit, Department of Surgery at the
Clinic Hospital of Barcelona were eligible to participate in this
trial (Fig. 1). Patients found to have unresectable disease and those
in whom surgery was converted to a different procedure after
laparotomy were excluded. Enrolled patients were randomized
to either the octreotide or the placebo group. The randomization
process was carried out during the operation by means of a ran-
domly generated number pattern. Patients in the octreotide group
received 100 mg subcutaneously during the operation (immedi-
ately after PD) and every 8 h after surgery for 10 days. Patients in
the placebo group received 31 perioperative doses of saline
administered in a similar manner.
Surgical technique
All procedures were performed by a team of surgeons specializing
in biliopancreatic surgery. All patients underwent pylorus-
preserving PD. The resection included division of the pancreas to
the left of the superior mesenteric and portal veins. In all patients
pancreatogastrostomy with an invagination anastomosis was per-
formed according to the gastric-partition technique (PG-GP).30,31
External drainage of the pancreatic duct with a silastic tube was
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Figure 1 Selection of the study sample according to the CONSORT (consolidated standards of reporting trials) template
HPB 393
HPB 2013, 15, 392–399 © 2012 International Hepato-Pancreato-Biliary Association
the Wirsung duct using an anchoring stitch (PDS 3/0; Ethicon,
Inc., Somerville, NJ, USA) to prevent catheter migration. A small
gastrotomy was made in the anterior gastric antrum to allow the
catheter to be externalized through a stab incision in the anterior
abdominal wall. A purse-string suture was used to close the gas-
trotomy site through which the catheter exited. The external end
of the tube was connected to a bottle on the floor to facilitate
the gravitational drainage of pancreatic juice. After PG-GP,
the remaining anastomoses (hepaticojejunostomy and gastro-
jejunostomy) were performed on the jejunal limb. Two peritoneal
drainage tubes (Jackson–Pratt silicone flat drain; Fortune Medical
Instrument Corp., Taipei Hsien, Taiwan) were placed so that one
was anterior and the other posterior to the pancreaticogastros-
tomy anastomosis. Another suction close drain (Jackson–Pratt)
was positioned posterior to the hepaticojejunostomy anastomosis.
Assessment of pancreatic characteristics
After the division of the pancreas, removal of the specimen and
mobilization of the pancreatic remnant, pancreatic consistency
and the diameter of the main pancreatic duct were assessed. The
pancreatic duct diameter was assessed according to a three-grade
classification system: pancreatic duct diameter grade 1 (<3 mm)
was assigned when a silastic tube of 2 mm in diameter precisely fit
in the duct; grade 2 (3–5 mm) was assigned when a silastic tube of
3 mm in diameter precisely fit in the duct but a silastic tube of
5 mm in diameter could be inserted with significant pressure, and
grade 3 (>5 mm) was assigned when a silastic tube of 5 mm in
diameter precisely fit in the duct. The assessment of pancreatic
consistency (hard or soft) was subjective and was based on visual
and tactile information gathered over the period of pancreatic
manipulation, and the placement of sutures during the pancrea-
ticogastrostomy reconstruction.
Data collection and perioperative management
Perioperative demographic and clinical data and details of the
operation, including information on pancreatic texture and duct
diameter, pathological diagnosis, postoperative course and com-
plications were collected prospectively. Clinically relevant POPF
was graded as B or C according to the International Study Group
on Pancreatic Fistula (ISGPF) grading system.32
Nasogastric tubes were removed at 5 days after surgery. For the
purpose of the study all patients were fasted for the first 10 days
after the operation. Oral solid diet was then resumed gradually if
there was no evidence of clinical POPF, delayed gastric emptying
(DGE) or other intra-abdominal complications.
Amylase levels in serum and drainage fluid were measured on
days 1, 3 and 5 after the operation and every week thereafter if
persistent clinical POPF was apparent. Intraperitoneal drainage
tubes were removed on day 5 if there was no evidence of anasto-
motic leakage.
Daily pancreatic juice output was measured for 10 days during
the postoperative period. Total daily lipase output in the pancre-
atic juice measured on postoperative day 3 was calculated by mul-
tiplying the concentration of the enzyme by the volume collected
in 24 h. Pancreatic lipase was determined by using commercial
turbidimetric assay kits (Randox Laboratories Ltd, Crumlin, UK),
according to the supplier’s specifications.
Study endpoints and definition
The primary study endpoint was the effect of perioperative octre-
otide given at the time of operation and subsequently every 8 h for
10 days, at a dose of 100 mg subcutaneously, on pancreatic
remnant exocrine secretion and the rate of development of POPF
in patients undergoing PD for pancreatic and periampullary
lesions. Clinically relevant POPF (grade B or C) was defined
according to ISGPF criteria32 as the presence of amylase-rich fluid
(more than three times the upper limit of normal serum levels) of
any measurable volume on or after day 3. Secondary endpoints
included overall morbidity, hospital mortality and duration of
postoperative hospital length of stay (LoS).
Statistical analysis
Previous studies predicted that somatostatin would decrease
mean pancreatic juice output from 200 ml to 50 ml per 24 h.29 It
was calculated that each group would be required to comprise 24
evaluable patients to give a and b errors of 5% each (95%
power).28,29 To ensure an adequate number of patients for all
analyses, the trial aimed to recruit a minimum of 30 patients to
each treatment group.
Patient demographic and clinical characteristics were com-
pared between the octreotide and placebo groups using X2 test or
Fisher’s exact test, as appropriate, for categorical variables and the
Mann–Whitney rank sum test for continuous variables. A P-value
of <0.05 was considered to indicate statistical significance. Statis-
tical analysis was performed using spss Version 19 (SPSS, Inc.,
Chicago, IL, USA).
Results
A total of 71 patients were scheduled for PD during the study
period (Fig. 1). Seven patients with an inflammatory mass of the
head of the pancreas for chronic pancreatitis and two patients
requiring conversion to a different operation (total pancreatec-
tomy) were excluded from the study. A total of 62 patients who
successfully underwent PD were finally randomized into the
octreotide (n = 32) and placebo (n = 30) groups. Table 1 shows
baseline demographic data for both patient groups. Table 2 shows
the distribution of duct diameters in relation to pancreatic
texture. Patients with pancreatic duct diameters of <3 mm (grade
1) and 3–5 mm (grade 2) were found to have a soft pancreas in
75.0% and 54.1% of cases, respectively (Table 2). Patients with a
pancreatic duct diameter of >5 mm (grade 3) were found to have
a hard pancreas in 72.7% of cases (grade 3 versus grades 1 and 2;
P < 0.01). Most patients with periampullary tumours (65.6%)
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were found to have a soft pancreas, whereas most patients with
adenocarcinoma (66.6%) had a hard pancreas.
Changes in exocrine secretion during treatment
Output of pancreatic juice increased steadily up to 3 days after the
operation; median total output during this early period was 40 ml
(range: 10–50 ml) in the octreotide group and 55 ml (range:
30–60 ml) in the placebo group. No significant differences in
median output during a relatively stable period (postoperative
days 4–10) emerged between the octreotide and placebo groups
(Table 3). When the patients were stratified according to patho-
logical diagnosis (adenocarcinoma versus periampullary tumour)
no significant differences in total output emerged between the
octreotide and placebo groups. However, adenocarcinoma
patients showed significantly less output (P < 0.004) compared
with patients with periampullary tumours in both the octreotide
and placebo groups. Table 4 shows that daily output did not
exceed 100 ml in the majority of adenocarcinoma patients, but
was higher in patients with periampullary tumours (P < 0.05).
When patients were categorized according to the diameter of the
main pancreatic duct, no significant differences in subgroups
emerged between the octreotide and placebo groups, but signifi-
cant differences (P < 0.001) emerged between patients with large
and small ducts, respectively (Table 5).
Table 1 Baseline demographics and diagnoses in the study sample
Octreotide group (n = 32) Placebo group (n = 30) P-value
Age, years, median (range) 69 (31–84) 69 (31–84) 0.950
Sex ratio, male : female 17:15 17:13 0.448
Body mass index, kg/m2, median (range) 23.8 (18.3–3.24) 23.6 (19.2–31.3) 0.928
Comorbid illness, n 15 16 1.000
Diagnosis, n
Pancreatic carcinoma 17 15 0.714
Ampullary carcinoma 4 6 0.617
Intraductal papillary mucinous neoplasm 2 3 1.000
Cholangiocarcinoma 3 1 0.617
Neuroendocrine tumour 2 1 0.617
Metastatic tumour 1 1
Duodenal cancer 1 1
Pseudopapillary solid tumour 1 1
Serous cystoadenoma 1 1
Biliary stenting, n 10 9 0.802
Table 2 Diameter of main pancreatic duct and pancreatic consistency in the study sample




Pancreatic texture Pancreatic texture
All, n Soft, n Hard, n All, n Soft, n Hard, n
Grade 1 (< 3 mm) 5 3 2 11 9 2
Grade 2 (3–5 mm) 9 3 6 15 10 5
Grade 3 (> 5 mm)a 16 4 12 6 2 4
aHard pancreas in grade 3 compared with grades 1 and 2 (P < 0.01).
Table 3 Pancreatic juice output in the study sample
Pancreatic juice output, ml/24 h, median (range)
Octreotide group (n = 32) Placebo group (n = 30) P-value
All patients (n = 62) 82 (50–250) 77 (50–250) 0.538
Pancreatic adenocarcinoma (n = 30) 50 (50–250) 46 (50–250) 0.401
Periampullary tumour (n = 32) 100 (50–250) 106 (50–250) 0.821
Pancreatic adenocarcinoma versus periampullary tumour 0.004
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Postoperative outcomes
Postoperative mortality was nil. Complications occurred in 21
patients. No significant differences were identified between
the two groups (Table 6). The most frequent complication was
DGE, which occurred in eight patients. The incidence of clinical
POPF was similar in both groups and occurred in patients with
a soft pancreas and a Wirsung duct size of < 3 mm. Hospital LoS
was similar in both groups (Table 6). Median lipase output
(U/24 h) on day 3 was lower in patients with adenocarcinoma
in both the octreotide [13 472 U (range: 2239–45 400 U)]
and placebo [14 452 U (range: 0–100 678 U)] groups than in
patients with periampullary tumours in the octreotide
[119 318 U (range: 4075–399 420 U)] and placebo [121 909 U
(range: 7422–229 333 U)] groups. However, the great variability
of results precluded the finding of any significant differences
between the octreotide and placebo groups in either patients
with adenocarcinoma or those with periampullary tumours
(P = 0.683).
Discussion
Somatostatin and its analogues decrease exocrine and endocrine
pancreatic secretion by binding the somatostatin receptors on the
exocrine and endocrine cells, and decrease the secretion of cells.33
It is assumed that decreasing the volume of pancreatic secretion
may decrease the incidence of pancreatic leak or fistula. The pro-
phylactic use of somatostatin and its analogues during and after
pancreatic surgery remains controversial. The role of somatostatin
delivered by i.v. infusion was investigated by Gouillat et al.28 and
Shan et al.29 in RCTs on the prevention of pancreas-related com-
plications after PD and changes in exocrine secretion during treat-
ment. In the study by Gouillat et al.,28 the analysis failed to
demonstrate a significant decrease in pancreatic juice output and
enzyme production, and therefore pancreatic exocrine secretion
following somatostatin infusion. In a similar study, Shan et al.29
found that: ‘. . . during the period of infusion of somatostatin, the
amount of exocrine secretion decreased to about 50% in the
somatostatin group in comparison to the placebo group within
the first 7 days with marginal significance (P = 0.0605).’
Early RCTs of somatostatin analogues favoured the use of
octreotide and found a decrease in pancreatic anastomotic
leaks.11–14 However, other studies reported no statistical benefit of
the perioperative use of octreotide.15–20 A recent meta-analysis of
RCTs on the efficacy of somatostatin and its analogues in the
prevention of postoperative complications after PD showed that
the use of pharmacological prophylaxis did not significantly
reduce incidences of pancreatic fistula, total pancreas-specific
complications, DGE, mortality or hospital LoS.27 These findings
are supported by a recent Cochrane review,24 which found no
Table 4 Daily output of pancreatic juice during postoperative days 1–10
Output, ml/day All patients Adenocarcinoma Periampullary tumour
Octreotide group Placebo group Octreotide group Placebo group Octreotide group Placebo group
(n = 32) (n = 30) (n = 17) (n = 15) (n = 15) (n = 15)
0–50 9 7 7 5 2 2
51–100 11 9 7 5 4 4
101–150 8 7 1 2 7 5
151–200 3 4 2 2 1 2
201–250 1 3 – 1 1 2
Table 5 Pancreatic juice output categorized according to main pancreatic duct diameter
Duct diameter Pancreatic juice output, ml/24 h, median (range) P-value
Octreotide group (n = 32) Placebo group (n = 30)
Grade 1 (< 3 mm) (n = 16) 90 (50–250) 93 (50–250) 0.880
Grade 2 (3–5 mm) (n = 24) 85 (50–250) 75 (50–250) 0.435
Grade 3 (> 5 mm) (n = 22) 46 (50–250) 48 (50–250) 0.813








Mortality, n 0 0
Morbidity, n 10 11 0.819
POPF Grade B, n 2 3 0.769
POPF Grade C, n – –
Biliary fistula, n 1 1 0.907
Delayed gastric emptying, n 4 4 0.918
Intra-abdominal abscess, n 1 1 1.000
Surgical site infection, n 2 2 1.000
Postoperative hospital stay, days 11.5 12.1 0.871
POPF, postoperative pancreatic fistula.
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differences in outcomes between the somatostatin analogue and
control groups and thus indicated a lack of effect.
The current study showed octreotide to lack efficacy in reduc-
ing the exocrine secretion of the remnant pancreas by collecting
and measuring the amount of diverted pancreatic juice. Pancreatic
exocrine secretion was significantly lower in patients with adeno-
carcinoma compared with patients with periampullary tumours.
In both groups of patients, total pancreatic juice output was not
influenced by the presence or absence of octreotide. Furthermore,
the current results support the findings of several RCTs that did
not show a clinically beneficial effect of octreotide prophylaxis in
terms of mortality, morbidity and postoperative hospital stay in
patients undergoing PD.15–21 This is of particular interest as cost
considerations become increasingly important in the manage-
ment of such patients.34
In the current study, the presence of pancreatic adenocarci-
noma was associated with a significant decrease in exocrine
pancreatic volume compared with periampullary tumours. The
present report also observed that pancreatic adenocarcinoma was
associated more frequently with a hard (66.6%) than a soft pan-
creatic texture. Matsumoto and Traverso35 found exocrine pancre-
atic insufficiency to be common (33%) in patients who require
PD. Further, 68% of patients with pancreatic adenocarcinoma
showed an abnormal secretory function based on stool elastase.35
Patients with pancreatic adenocarcinoma are considered to be at
low risk for pancreatic complications.
It has been suggested that the prophylactic use of octreotide
may have a particular benefit in patients at high risk for the
occurrence of pancreatic complications after PD.34 These high-
risk patients are typically considered to be those lacking paren-
chymal fibrosis, specifically patients with a soft pancreatic texture,
undergoing resection for duodenal cancer, ampullary tumours,
cystic neoplasms or islet cell tumours.36–38 A recent RCT39 com-
paring pancreaticojejunostomy with invagination versus duct-to-
mucosa anastomosis in patients stratified by pancreatic texture
showed that soft texture was an independent risk factor for POPF.
A soft parenchyma is often associated with a small, non-dilated
pancreatic duct and well-preserved exocrine pancreatic func-
tion.40 Several studies have shown that normal pancreatic exocrine
function is a risk factor for anastomotic leakage according to the
objective assessment of pancreatic function.41–45 Hamanake et al.46
described a higher risk for pancreatic anastomotic leakage and a
greater amount of pancreatic juice from pancreatic ductal drain-
age in patients with a pancreas of intermediate or normal consist-
ency compared with those with a pancreas of hard consistency.
The classification of pancreatic texture is relatively subjective
and lacks objective criteria.47 In the present investigation, the size
of the pancreatic duct was also used to stratify patients. Duct size
was found to correlate strongly with pancreatic texture. Duct
diameters of <3 mm (grade 1) and 3–5 mm (grade 2) were asso-
ciated with a soft pancreas in the majority of patients. However, a
grade 3 duct diameter (>5 mm) was associated significantly more
strongly with a hard pancreas (P < 0.01). To the authors’ knowl-
edge, this is the first study to report the relationship between the
diameter of the Wirsung duct and pancreatic juice output.
Outputs of pancreatic juice were similar in patients with duct
diameters of grades 1 and 2. However, total output was signifi-
cantly lower in patients with grade 3 duct diameters compared
with those with grade 1 or 2 duct diameters. In all duct diameter
grade groups, total pancreatic juice output was not influenced by
the presence or absence of octreotide.
Conclusions
The current study demonstrates the lack of efficacy of octreotide
in reducing the exocrine secretion of the remnant pancreas after
PD. In addition, it confirms the correlation between pathological
diagnosis and exocrine pancreatic function after PD. Pancreati-
coduodenectomy for pancreatic adenocarcinoma was significantly
associated with greater dilatation of the pancreatic duct and a
harder pancreas, as well as with a lower output of pancreatic juice
compared with PD for periampullary tumours. Therefore, the
assumption that pancreatic cancer increases the risk for fistula is
probably not justified because it appears to offer a protective
effect. A soft parenchyma and non-dilated pancreatic duct are
shown to be associated with well-preserved exocrine pancreatic
secretion and represent important risk factors for POPF.
This study corroborates the findings of previous studies that
similarly reported a lack of efficacy of octreotide in patients
undergoing PD.15–21 Prophylactic octreotide use does not decrease
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